Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR4640 plus febuxostat versus febuxostat dose escalation in primary gout with hyperuricemia uncontrolled on febuxostat 40 mg
CTR20260182Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruzinurad, febuxostat in gout, hyperuricemia, sponsored by Hengrui Therapeutics. Started Mar 2026; status: active.
02
Drugs
ruzinuradfebuxostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20260182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260182.